Apply Give

Other ways to search: Events Calendar | UTHSC

Leadiant Biosciences Is Conducting the Registry Study of Revcovi® Treatment in Patients With ADA-SCID

Written by Communications and Marketing

|

Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi®(elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID). The registry study will follow pediatric and adult ADA-SCID patients for two years or longer to collect supplemental information on those being treated with Revcovi… “The information obtained through this registry study will provide additional knowledge and tools to help patients with this devastating disease. Through this ongoing research, we hope to better understand Revcovi, with the goal of benefitting patients in the future,” commented Jay Lieberman, MD, immunologist with LeBonheur Children’s Hospital and The University of Tennessee Health Sciences Center in Memphis.

Top Publishers